TG4050 is an individualized therapeutic vaccine

A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate.


First clinical benefits
in head and neck cancer
– Proof of principle data —

One cancer, one patient, one vaccine

With TG4050, Transgene is developing an individualized immunotherapy based on advanced genetic engineering and artificial intelligence (AI) technologies.
The treatment is based on an optimized MVA viral vector.

myvac® video

Each treatment is designed and manufactured by Transgene for each patient, targeting the most relevant tumor targets (cancer-specific neoantigens) selected by NEC’s AI.

Once injected into the patient, this therapeutic vaccine will stimulate the patient’s immune defenses to allow the targeted destruction of cancer cells.

To carry out this project, Transgene relies on a unique expertise, a network of prestigious and recognized partners at every stage of product development and integrated manufacturing capabilities.

–> article annonce 28362 ou substitut 28368

Collaboration agreements

Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each patient, on the basis of mutations identified through sequencing of tumor tissue, prioritized using NEC’s Neoantigen Prediction System and delivered using Transgene’s myvac® technological platform which allows development and manufacturing.

Clinical trials


HPV-negative head and neck cancers – after surgery and adjuvant therapyPhase I/IIMore information

Transgene sa
400 Boulevard Gonthier d’Andernach - Parc d'Innovation - CS80166
67405 Illkirch Graffenstaden Cedex - France |
Tel. : + 33 (0) 3 88 27 91 00


© 2023 Transgene - All rights reserved